FILKRI (filgrastim-laha)
LEUKOCYTE STIMULATING FACTORS·SEVERE CHRONIC NEUTROPENIA·+7
ACCORD BIOPHARM
Indication
Chemotherapy-induced neutropenia
Chemotherapy-induced neutropenia is a common hematologic complication of cytotoxic cancer therapy, characterized by an abnormally low absolute neutrophil count in the peripheral blood. Read more about Chemotherapy-induced neutropenia
10 drugs 6 manufacturers
Drugs that treat it
Common Chemotherapy-induced neutropenia therapies.
Filter & compare in the drug finder →Opens the drug finder with Chemotherapy-induced neutropenia preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonChemotherapy-induced neutropenia is a common hematologic complication of cytotoxic cancer therapy, characterized by an abnormally low absolute neutrophil count in the peripheral blood.
It primarily affects oncology patients receiving myelosuppressive antineoplastic regimens that impair hematopoietic stem and progenitor cell proliferation in the bone marrow.
Pathophysiologically, the transient destruction of rapidly dividing myeloid precursors depletes circulating innate immune cells, typically reaching a nadir within one to two weeks following treatment.
Clinically, this suppression significantly impairs host defense mechanisms, predisposing patients to severe infections, febrile neutropenia, and dose-limiting chemotherapy delays or reductions.
- nih.gov
Chemotherapy-induced neutropenia is a common hematologic complication of cytotoxic cancer therapy, characterized by an abnormally low absolute neutrophil count in the peripheral blood
- cancernetwork.com
Chemotherapy-induced neutropenia is a common hematologic complication of cytotoxic cancer therapy, characterized by an abnormally low absolute neutrophil count in the peripheral blood
- healthline.com
It primarily affects oncology patients receiving myelosuppressive antineoplastic regimens that impair hematopoietic stem and progenitor cell proliferation in the bone marrow
- patientpower.info
It primarily affects oncology patients receiving myelosuppressive antineoplastic regimens that impair hematopoietic stem and progenitor cell proliferation in the bone marrow Pathophysiologically, the transient destruction of rapidly dividing myeloid precursors depletes circulating innate immune cells, typically reaching a nadir within one to two weeks following treatment
- uspharmacist.com
Pathophysiologically, the transient destruction of rapidly dividing myeloid precursors depletes circulating innate immune cells, typically reaching a nadir within one to two weeks following treatment
- nih.gov
Clinically, this suppression significantly impairs host defense mechanisms, predisposing patients to severe infections, febrile neutropenia, and dose-limiting chemotherapy delays or reductions
- nih.gov
Clinically, this suppression significantly impairs host defense mechanisms, predisposing patients to severe infections, febrile neutropenia, and dose-limiting chemotherapy delays or reductions
Personalize your experience
Follow Chemotherapy-induced neutropenia and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.